Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/IIa open-label dose-escalation and dose-expansion study of Budoprutug (TNT119) in adults with systemic lupus erythematosus
CTR20261708Phase 2Active
- Sponsor
- Climb Bio
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of budoprutug in systemic lupus erythematosus (SLE), sponsored by Climb Bio. Started May 2026; status: active.
02
Drugs
budoprutug
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20261708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261708.